Thurston Springer Miller Herd & Titak Inc. Grows Stock Position in Inotiv, Inc. (NASDAQ:NOTV)

Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Inotiv, Inc. (NASDAQ:NOTV - Free Report) by 612.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 127,257 shares of the company's stock after purchasing an additional 109,397 shares during the period. Thurston Springer Miller Herd & Titak Inc. owned about 0.49% of Inotiv worth $527,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. American Century Companies Inc. boosted its position in Inotiv by 109.6% during the 2nd quarter. American Century Companies Inc. now owns 295,589 shares of the company's stock valued at $491,000 after acquiring an additional 154,541 shares in the last quarter. King Luther Capital Management Corp boosted its position in Inotiv by 101.4% during the second quarter. King Luther Capital Management Corp now owns 198,600 shares of the company's stock valued at $330,000 after purchasing an additional 100,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in Inotiv by 29.9% in the second quarter. Renaissance Technologies LLC now owns 164,164 shares of the company's stock valued at $273,000 after purchasing an additional 37,800 shares during the last quarter. Geode Capital Management LLC raised its holdings in Inotiv by 7.7% in the third quarter. Geode Capital Management LLC now owns 250,895 shares of the company's stock worth $427,000 after purchasing an additional 18,039 shares in the last quarter. Finally, KPP Advisory Services LLC lifted its position in shares of Inotiv by 4.5% during the second quarter. KPP Advisory Services LLC now owns 238,138 shares of the company's stock valued at $395,000 after buying an additional 10,347 shares during the last quarter. 18.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital upgraded shares of Inotiv from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $2.00 to $4.00 in a research note on Monday, September 30th.

Inotiv Stock Up 1.4 %

Inotiv stock traded up $0.06 during midday trading on Thursday, reaching $4.32. The company's stock had a trading volume of 1,395,473 shares, compared to its average volume of 813,317. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a market capitalization of $112.36 million, a P/E ratio of -1.03 and a beta of 3.59. The stock's 50-day simple moving average is $4.04 and its 200-day simple moving average is $2.53. Inotiv, Inc. has a 52-week low of $1.23 and a 52-week high of $11.42.

Insider Activity at Inotiv

In other news, COO John Gregory Beattie bought 30,000 shares of Inotiv stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of $4.75 per share, for a total transaction of $142,500.00. Following the purchase, the chief operating officer now directly owns 161,761 shares of the company's stock, valued at approximately $768,364.75. The trade was a 22.77 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael J. Harrington acquired 10,000 shares of the business's stock in a transaction dated Friday, December 6th. The stock was purchased at an average cost of $3.98 per share, for a total transaction of $39,800.00. Following the completion of the acquisition, the director now directly owns 37,500 shares of the company's stock, valued at approximately $149,250. This trade represents a 36.36 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 71,029 shares of company stock valued at $314,248 in the last three months. 5.80% of the stock is owned by insiders.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.